A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

Efficient antitumour immunity is dependent upon the orchestration of potent T cell responses towards malignancies1. Regression of human cancers has been induced by immune checkpoint inhibitors, T cell engagers or chimeric antigen receptor T cell therapies2-4. Though CD8 T cells operate as key effectors of those responses, the function of CD4 T cells past their…

Read More